Preliminary experience on the use of the adnatest® system for detection of circulating tumor cells in prostate cancer patients

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3507-3513

  Todenhöfer, Tilman ^a   Hennenlotter, Jörg ^a   Feyerabend, Susan ^a   Aufderklamm, Stefan ^a   Mischinger, Johannes ^a   Kühs, Ursula ^a   Gerber, Valentina ^a   Fetisch, Jasmin ^b   Schilling, David ^a   Hauch, Siegfried ^b   Stenzl, Arnulf ^a   Schwentner, Christian ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Adnagen GmbH   (Germany)

Author keywords

Adnatest; Chemotherapy; CTC; Prognosis; Prostate cancer; Response

Indexed keywords

ALDEHYDE DEHYDROGENASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DISEASE COURSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WHOLE BODY CT;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RNA, MESSENGER; TAXOIDS;

EID: 84865680531     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F and Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583, 2011.
2. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R and Eisenberger M: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25: 3965-3970, 2007.
3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
4. Bellmunt J, Rosenberg JE and Choueiri TK: Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 56: 606-608, 2009.
5. Danila DC, Fleisher M and Scher HI: Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17: 3903-3912, 2011.
6. Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C and Koutsilieris M: Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15: 101-114, 2009.
7. Miller MC, Doyle GV and Terstappen LW: Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010: 617421, 2010.
8. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M and Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053-7058, 2007.
9. Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS and Kaul KL: Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 158: 1870-1874; discussion 1874-1875, 1997.
10. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA and Cristofanilli M: Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 2011.
11. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, Maes H, Huget P, van Dam P, Vermeulen PB and Dirix LY: Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102: 276-284, 2010.
12. Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 8: 428-439, 2011.
13. Wang ZA and Shen MM: Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 30: 1261-1271, 2011.
14. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
15. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A and Hussain M: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008.
16. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Vaananen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI and Lilja H: Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 55: 765-773, 2009.
17. Thomas J, Gupta M, Grasso Y, Reddy CA, Heston WD, Zippe C, Dreicer R, Kupelian PA, Brainard J, Levin HS and Klein EA: Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 20: 3213-3218, 2002.
18. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K and Tomita Y: Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 8: 1794-1799, 2002.
19. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S and Foekens JA: Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 118: 455-468, 2009.
20. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10: 233-239, 2009.
21. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K and Kantoff PW: Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgenin-dependent prostatic carcinoma. Urology 50: 100-105, 1997.
22. Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM and Slawin KM: Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res 62: 5974-5979, 2002.
23. Doyen J, Alix-Panabieres C, Hofman P, Parks SK, Chamorey E, Naman H and Hannoun-Levi JM: Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. Crit Rev Oncol Hematol 2011.
24. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309, 2008.
25. Gravina GL, Marampon F, Piccolella M, Biordi L, Ficorella C, Motta M, Jannini EA, Tombolini V and Festuccia C: Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib. Prostate 2011.
26. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brummendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G and Schlomm T: Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16: 1553-1560, 2010.
27. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, Bischoff FZ and Pircher TJ: Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol 2011: 252361, 2011.
28. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J and Xu Y: Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137: 1151-1173, 2011.
29. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46, 2009.
30. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R and Fehm T: Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14: R15, 2012.
31. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ and Garcia-Blanco MA: Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9: 997-1007, 2011.
32. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E and Gazzaniga P: Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130: 449-455, 2011.
33. Kallergi G, Mavroudis D, Georgoulias V and Stournaras C: Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13: 79-88, 2007.